ORGS Stock Overview
A biotech company, focuses on cell and gene therapies worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Orgenesis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.52 |
| 52 Week High | US$1.08 |
| 52 Week Low | US$0.25 |
| Beta | 1.22 |
| 11 Month Change | -29.41% |
| 3 Month Change | -10.85% |
| 1 Year Change | -16.55% |
| 33 Year Change | -89.69% |
| 5 Year Change | -88.43% |
| Change since IPO | 1,272.27% |
Recent News & Updates
Recent updates
Orgenesis Inc.'s (NASDAQ:ORGS) Price Is Right But Growth Is Lacking After Shares Rocket 119%
Mar 04
Orgenesis GAAP EPS of $0.22 beats by $0.24, revenue of $7.2M beats by $0.2M
Aug 16Orgenesis gets FDA IDE approval for Tissue Genesis Icellator COVID-19 study
May 06Orgenesis shares rise after Bambino Gesù Children's Hospital collaboration
Apr 30Orgenesis (NASDAQ:ORGS) Has Debt But No Earnings; Should You Worry?
Feb 05
Orgenesis: A Cell And Gene Therapy Disruptor With A Nice Risk Reward Profile
Jan 28Did You Miss Orgenesis' (NASDAQ:ORGS) 71% Share Price Gain?
Dec 14Shareholder Returns
| ORGS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.0% | -1.3% | 1.2% |
| 1Y | -16.5% | 23.2% | 30.2% |
Return vs Industry: ORGS underperformed the US Biotechs industry which returned 23.2% over the past year.
Return vs Market: ORGS underperformed the US Market which returned 30.2% over the past year.
Price Volatility
| ORGS volatility | |
|---|---|
| ORGS Average Weekly Movement | 17.7% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ORGS's share price has been volatile over the past 3 months.
Volatility Over Time: ORGS's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 146 | Vered Caplan | orgenesis.com |
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals.
Orgenesis Inc. Fundamentals Summary
| ORGS fundamental statistics | |
|---|---|
| Market cap | US$24.28m |
| Earnings (TTM) | -US$29.02m |
| Revenue (TTM) | US$662.00k |
36.7x
P/S Ratio-0.8x
P/E RatioIs ORGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORGS income statement (TTM) | |
|---|---|
| Revenue | US$662.00k |
| Cost of Revenue | US$1.33m |
| Gross Profit | -US$669.00k |
| Other Expenses | US$28.35m |
| Earnings | -US$29.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.62 |
| Gross Margin | -101.06% |
| Net Profit Margin | -4,383.23% |
| Debt/Equity Ratio | -70.8% |
How did ORGS perform over the long term?
See historical performance and comparison